Dyskinesias associated with atomoxetine in combination with other psychoactive drugs

Clinical Toxicology

Volumn 45, Issue 2, 2007, Pages 182-185

  Bond, G Randall ^a,c   Garro, Aris C ^a,b   Gilbert, Donald L ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b BROWN UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

ADHD; Atomoxetine; Movement disorder; Toxicity

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; DIPHENHYDRAMINE; PAROXETINE; SERTRALINE; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARNOLD CHIARI MALFORMATION; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; COMPULSION; DECREASED APPETITE; DRUG DOSE INCREASE; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PANIC; SCHOOL CHILD; SLEEP DISORDER; TREMOR; VOMITING;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DIPHENHYDRAMINE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; PROPYLAMINES; PSYCHOTROPIC DRUGS; TREATMENT OUTCOME;

EID: 33847158418     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.1080/15563650600981178     Document Type: Article

References (19)

1. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285:60-66.
2. Goldman LS, Genel M, Bezman RJ, Slanetz PJ. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. JAMA 1998; 279:1100-1107.
3. Lee TSW, Lee TD, Lombroso PJ, King RA. Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 2004; 43:1068-1069.
4. Spiller HA, Lintner CP, Winter ML. Atomoxetine (Strattera) exposure in children (abstract). J Toxicol Clin Toxicol 2004; 42:720.
5. Caballero J, Nahata MC. Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25:3065-3083.
6. Anonymous. Atomoxetine (Strattera) revisited. Medical Letter on Drugs & Therapeutics 2004; 46:65.
7. Henderson TA, Hartman K. Aggression, mania, and hypomania induction associated with atomoxetine. Pediatrics 2004; 114:895-896.
8. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25:296-301.
9. Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metabolism & Disposition 2002; 30:319-323.
10. Belle DJ, Ernest CS, Sauer JM, et al. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol 2002; 42:1219-1227.
11. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155:1325-1331.
12. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27:699-711.
13. Extein I. Methylphenidate-induced choreoathetosis. Am J Psychiatry 1978; 135:252-253.
14. Weiner WJ, Nausieda PA, Klawans HL. Methylphenidate-induced chorea: case report and pharmacologic implications. Neurology 1978; 28:1041-1044.
15. Klawans HL, Weiner WJ. The effect of d-amphetamine on choreiform movement disorders. Neurology 1974; 24:312-318.
16. Mattson RH, Calverley JR. Dextroamphetamine-sulfate-induced dyskinesias. JAMA 1968; 204:400-402.
17. Burd L, Kerbeshian J. Stuttering and stimulants. J Clin Psychopharmacol 1991; 11:72-73.
18. Boyer EW, Shannon M. The Serotonin Syndrome. N Engl J Med 2005; 352:1112-1120.
19. Sauer JM, Long AJ, Ring B, Gillespie JS, Sanburn ND, DeSante KA, Petullo D, VandenBranden MR, Jensen CB, Wrighton SA, Smith BP, Read HA, Witcher JW. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. Journal of Pharmacology & Experimental Therapeutics 2004; 308:410-418.